
Avient Corp (AVNT) Stock Forecast & Price Target
Avient Corp (AVNT) Analyst Ratings
Bulls say
Avient Corp has demonstrated robust performance, with organic sales increasing by 5%, supported significantly by its healthcare segment, which reported double-digit growth for six consecutive quarters, culminating in a 14% year-over-year increase in the first half of 2025. Additionally, four out of nine end markets, contributing to 40% of Avient's sales, are on a growth trajectory this year, while total organic sales are projected to rise by approximately 2% in 2025. Despite anticipated challenges in the consumer end market for the second half of 2025, the overall diversification in Avient’s product portfolio across various industries positions the company favorably for sustained revenue growth.
Bears say
Avient Corp has experienced a decline in organic sales, posting a decrease of approximately 2% in the first quarter of 2024, with subsequent growth in the following quarters failing to compensate for this initial drop, raising concerns about overall revenue stability. The company faces weakening demand in the chemicals sector, with anticipated downside risks to volume in the second half of 2025, which could further impact financial performance. Despite a declining dollar potentially providing some support, the fundamentals indicate significant challenges ahead for Avient's revenue and market position.
This aggregate rating is based on analysts' research of Avient Corp and is not a guaranteed prediction by Public.com or investment advice.
Avient Corp (AVNT) Analyst Forecast & Price Prediction
Start investing in Avient Corp (AVNT)
Order type
Buy in
Order amount
Est. shares
0 shares